Allakos Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 131
- Market Cap
- $62.1M
- Website
- http://www.allakos.com
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
- Conditions
- Eosinophilic GastritisEosinophilic GastroenteritisEosinophilic Duodenitis
- Interventions
- Drug: AK002
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03664960
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
- Conditions
- Eosinophilic GastritisEosinophilic Gastroenteritis
- Interventions
- Other: PlaceboDrug: AK002
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT03496571
- Locations
- 🇺🇸
Ventura Clinical Trials, Ventura, California, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Riverside Clinical Research, Edgewater, Florida, United States
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
- Conditions
- Chronic Urticaria
- Interventions
- Drug: AK002
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03436797
- Locations
- 🇩🇪
Allakos Investigational Site, Mainz, Germany
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
- Conditions
- Perennial Allergic ConjunctivitisAtopic KeratoconjunctivitisVernal Keratoconjunctivitis
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03379311
- Locations
- 🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
🇺🇸Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸Ophthalmology Associates, Saint Louis, Missouri, United States
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: AK002Other: Placebo
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02859701
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Australia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
- Conditions
- Indolent Systemic Mastocytosis
- Interventions
- Drug: AK002
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02808793
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
- Conditions
- Nasal Polyposis
- Interventions
- Drug: AK001 low doseDrug: AK001 high doseDrug: Placebo
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02734849
- Locations
- 🇬🇧
Investigator site, Manchester, United Kingdom
🇪🇸Investigator, Valencia, Spain
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001
- Conditions
- Atopy
- Interventions
- Drug: AK001Drug: Placebo
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Allakos Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02563938